The 4-1BBL can induce anti-tumor activities by promoting CD8 T cell expansion and protect against autoimmunity and transplantation rejection by depletion NK and B cells. The 4-1BB/4-1BBL pathway is a potential therapeutic target for oncology and autoimmune disorders.
Interacting protein(s): 4-1BB
Related products: Hexa-Ligand
Read all details below including Quick Specs.
** Please note: For orders over 1 mg, please inquire here
|Tag:||Aglycosylated mouse IgG2a Fc|
|Construction:||Aglycosylated mouse IgG2a Fc-GIL-Human 4-1BBL (A50–E254)-AAL|
|MW (calculated):||48287 daltons|
|MW (SDS-PAGE):||52 Kd|
|Abs 0.1% (= 1 mg/ml):||1.147|
Murine 4-1BB ligand was initially cloned by expression cloning form a cDNA library of EL4 thymoma cells using 4-1BB-Fc fusion protein. The 4-1BB Ligand is a member of the TNF superfamily (TNFSF). It carboxyl terminal extracellular domain contains three N-glycosylation sites. In addition, its membrane proximal region is rich in threonine, serine and proline residues which is indicative of O-linked glycosylation site.
Interestingly, both human and mouse 4-1BB ligand are among the least homologous member of the TNF superfamily. While earlier studies indicated that 4-1BB ligand might be an exception within the TNFSF and exists as dimeric protein. Subsequent studies shows the soluble trimeric ligand interacts with 4-1BB just like other TNFSF/TNFRSF pairs.
The anti-tumor effect of the 4-1BB/4-1BBL axis is based on the observation that 4-1BBL stimulates activated T cells, particularly CD8 T cells and induces secretion of high levels of IFN-g even though the potential adverse effects of inducing autoimmune status has to be considered at all time. Interestingly, in vivo administration of agonistic anti-4-1BB antibody leads to depletion of B, NK, and CD4 T cells. Hence, 4-1BBL can promote CD8 T cell expansion as well as protect against autoimmune and transplantation rejection. The 4-1BB/4-1BBL pathway is an import